Matching articles for "brexucabtagene autoleucel"
Issue 1718 · December 23, 2024 Free
In Brief: Obecabtagene Autoleucel (Aucatzyl) - Another CAR-T Cell Immunotherapy for ALL (online only)

Obecabtagene autoleucel ( Aucatzyl – Autolus), a CD19-directed genetically modified autologous T cell immunotherapy, has been approved by the FDA for treatment of relapsed or refractory B-cell precursor…

Med Lett Drugs Ther. 2024 Dec 23; 66(1718):e208 doi:10.58347/tml.2024.1718f
Obecabtagene autoleucel ( Aucatzyl – Autolus), a CD19-directed genetically modified autologous T cell immunotherapy, has been approved by the FDA for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. The CAR T-cell immunotherapy products tisagenlecleucel (Kymriah) and brexucabtagene auto-leucel (Tecartus) were approved earlier for the same indication.
Issue 1678 · June 12, 2023 Free
In Brief: Brexucabtagene autoleucel (Tecartus) for Acute Lymphoblastic Leukemia (online only)

Brexucabtagene autoleucel ( Tecartus – Kite) has been approved by the FDA for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It was previously approved…

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):e105-6 doi:10.58347/tml.2023.1678f
Brexucabtagene autoleucel ( Tecartus – Kite) has been approved by the FDA for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It was previously approved for treatment of relapsed or refractory mantle cell lymphoma. Tecartus is an individualized cellular product prepared from the patients own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. The CAR T-cell immunotherapy tisagenlecleucel (Kymriah) was approved in 2017 for treatment of relapsed or refractory B-cell precursor ALL in patients ≤25 years old.